While in an orthotopic xenograft model, an intrathecally administered cytotoxin saporin-conjugated antibody targeting PTPRZ1 delayed tumor growth of an intracranially injected human glioma cell line [143], following TCR discovery and validation, therapeutic efficacy of PTPRZ1-targeting TCRs is yet to be demonstrated. Here, PTPRZ1 is linked to central nervous system cancer.